Results 81 to 90 of about 10,985 (213)

Nongenotoxic 3-Nitroimidazo[1,2-a]pyridines Are NTR1 Substrates That Display Potent in Vitro Antileishmanial Activity [PDF]

, 2019
Twenty nine original 3-nitroimidazo[1,2-a]pyridine derivatives, bearing a phenylthio (or benzylthio) moiety at position 8 of the scaffold, were synthesized.
Azas, Nadine, Basmaciyan, Louise, Belle Mbou, Valère, Boudot, Clotilde, Bourgeade-Delmas, Sandra, Boutet-Robinet, Élisa, Casanova, Magali, Castera-Ducros, Caroline, Cohen, Anita, Courtioux, Bertrand, Fairlamb, Alan H., Fersing, Cyril, Hutter, Sébastien, Laget, Michèle, Milne, Rachel, Pedron, Julien, Piednoel, Mélanie, Primas, Nicolas, Rathelot, Pascal, Since, Marc, Sournia-Saquet, Alix, Valentin, Alexis, Vanelle, Patrice, Verhaeghe, Pierre, Wyllie, Susan   +24 more
core   +4 more sources

Comparing the Effects of Topical Miltefosine and Glucantime in Treatment of Cutaneous Leishmaniasis

مجله دانشکده پزشکی اصفهان, 2014
Background: Due to the limited number of studies, failure to adequately investigating the impact of miltefosine in the treatment of cutaneous leishmaniasis, and the fact that faster recovery of injuries causes less scarring for the patient, the present ...
Ali Asilian, Shaghayegh Omrani, Mohammad Ail Nilforoushzadeh   +2 more
doaj  

Advanced case of PKDL due to delayed treatment: A rare case report.

PLoS Neglected Tropical Diseases, 2020
Post-kala-azar dermal leishmaniasis (PKDL) is clinical outcome of visceral leishmaniasis (VL) and is thought to be the potential reservoir of parasite. Miltefosine (MF) is the only oral drug existing for treatment of post-kala-azar dermal leishmaniasis ...
Roshan Kamal Topno, Vidya Nand Rabi Das, Maneesh Kumar, Major Madhukar, Krishna Pandey, Neena Verma, Kanhaiya Agrawal, Chandra Shekhar Lal, Niyamat Ali Siddiqui, Sanjiva Bimal, Pradeep Das   +10 more
doaj   +1 more source

In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal : genomic and metabolomic characterization [PDF]

, 2015
n this study, we followed the genomic, lipidomic and metabolomic changes associated with the selection of miltefosine (MIL) resistance in two clinically derived Leishmania donovani strains with different inherent resistance to antimonial drugs (antimony ...
Blackburn, G., Carter, K. C., Coombs, G. H., Cotton, J. A., Downing, T., Dujardin, J. C., Freeman, T. M., Illingworth, C. J. R., Imamura, H., Khanal, B., Lonchamp, J., Rijal, S., Sanders, M., Shaw, C. D.   +13 more
core   +8 more sources

Estudo comparativo entre miltefosina oral e antimoniato de N-metil glucamina parenteral no tratamento da leishmaniose experimental causada por Leishmania (Leishmania) amazonensis Comparative study between oral miltefosine and parenteral N-metil glucamine antimoniate for the treatment of experimental leishmaniasis caused Leishmania (Leishmania) amazonensis

Revista da Sociedade Brasileira de Medicina Tropical, 2008
Vinte e cinco camundongos infectados com Leishmania amazonensis foram tratados com antimoniato de N-metil glucamina e miltefosina oral. Critérios: medidas das patas, pesquisa de amastigotas e culturas após-tratamento.
Arnoldo Velloso da Costa Filho, Íris Campos Lucas, Raimunda Nonata Ribeiro Sampaio   +2 more
doaj   +1 more source

Leishmania and other intracellular pathogens: selectivity, drug distribution and PK-PD. [PDF]

, 2017
New drugs and treatments for diseases caused by intracellular pathogens, such as leishmaniasis and the Leishmania species, have proved to be some of the most difficult to discover and develop.
Croft, Simon L
core   +1 more source

Drug Resistance in Eukaryotic Microorganisms [PDF]

, 2016
Eukaryotic microbial pathogens are major contributors to illness and death globally. Although much of their impact can be controlled by drug therapy as with prokaryotic microorganisms, the emergence of drug resistance has threatened these treatment ...
A Abdolrasouli, A Cassone, A Chowdhary, A Ecker, A Heinberg, A Kulshrestha, A Mbengue, A Mukherjee, A Selmecki, A Selmecki, A Trochine, AC Coelho, AF Cowman, AF Cowman, AH Fairlamb, AH Fairlamb, AJ Kazibwe, AM Abd-Alla, AM Dondorp, AM Mejia, AY Sokolova, B Chawla, B Gourbal, B Zingales, BD Alexander, BJ Kullberg, BK Kubata, BM Mony, BS Hall, BS Hall, BS McGwire, C Amaratunga, C Amaratunga, C Brochu, C Costa, C Mathieu, C Sisowath, C Wongsrichanalai, CA Morillo, CD Goodman, CF Oliva, CP Sanchez, CP Sanchez, D Begolo, D Rojo, DA Fidock, DS Guttery, DS Perlin, DW Denning, E Castanys-Munoz, E Chatelain, E Kussell, E Matovu, E Shor, E Snelders, E Snelders, E Vermeulen, E Wang, F Ariey, F Nosten, FC Odds, FE Graf, FE Graf, FJ Perez-Victoria, FJ Perez-Victoria, FJ Perez-Victoria, FM Fernandez, G Awasthi, G Blum, G Priotto, GA Canuto, GA Pankey, GM Nayyar, GW Rose, H Noedl, HL Callahan, HM Andrade, HY Sun, I Keren, I Molina, IH Cheeseman, IM Vincent, IM Vincent, IM Vincent, J Hemingway, J Robays, J Song, J Straimer, J Yuan, JA Urbina, JA Urbina, JC Dias, JC Dias, JC Munday, JC Wootton, JI Manzano, JL Nishikawa, JM Perez-Victoria, JR Franco, JW van der Linden, K El Fadili, K Lewis, K Seifert, KC Gray, KJ Kwon-Chung, KW Dantzler, L Denoeud-Ndam, L Glover, LE Cowen, LE Cowen, M Berg, M Ghorbal, M Maharjan, M Manske, M Plourde, M Rakotomanga, M Rakotomanga, M Venkatesan, M Woolhouse, M Woolhouse, MA Pfaller, MB Rogers, MC Brotherton, MD LaFleur, MD LaFleur, MK Kinga, MK Laufer, MR Perry, MR Perry, MR Perry, MT Duraisingh, MT Ferdig, N Baker, N Biyani, N Marquis, N Regev-Rudzki, N Rovira-Graells, NJ White, NR Cohen, NS Carter, O Epaulard, O Miotto, P Baiocco, P Maser, P Shaked-Mishan, P Vandeputte, P Wang, PE Verweij, PJ Hotez, PK Fyfe, PL Olliaro, PP Pyana, PY Mantel, R Kumar, R Mukhopadhyay, R Prasad, RD Cannon, S Alsford, S Decuypere, S Decuypere, S Dey, S Dey, S Imhof, S Kucharikova, S Leroux, S Mandal, S Mok, S Patterson, S Pelleau, S Pulcini, S Rijal, S Sundar, S Sundar, S Takala-Harrison, S Wyllie, S Wyllie, S Wyllie, S Wyllie, SA Flowers, SC Welburn, SD Singh, SE Kidd, SG Valderramos, SK Katiyar, SMF Murta, SR Meshnick, SR Wilkinson, TE Wellems, TE Wellems, TPC Dorlo, V Lutje, W Peters, Y Sterkers, Y Zhou   +193 more
core   +4 more sources

Oral miltefosine for refractory Acanthamoeba keratitis

American Journal of Ophthalmology Case Reports, 2019
Purpose: To report the first case of Acanthamoeba keratitis treated with oral miltefosine in the United States. Observations: A 17-year-old female with a history of orthokeratology contact lens wear presented after five months of left eye pain, redness ...
Kristin E. Hirabayashi, Charles C. Lin, Christopher N. Ta   +2 more
doaj   +1 more source

Interactions of Miltefosine and Phospholipid DPPC at the Air/Water Interface [PDF]

, 2009
Advisor: Maria BohorquezSeveral Langmuir monolayer studies have suggested that the drug Hexadecylphosphocholine (miltefosine) has a mode of action which is directly related to the cell membrane.
Wildgen, Sarah M.
core   +1 more source

Thermoterapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia

Revista do Instituto de Medicina Tropical de São Paulo, 2013
In Colombia, pentavalent antimonials and miltefosine are the drugs of choice for the treatment of cutaneous leishmaniasis; however, their toxicity, treatment duration, (treatment adherence problems), cost, and decreased parasite sensitivity make the ...
Liliana López, Claudia Cruz, Gonzalo Godoy, Sara M. Robledo, Iván D. Vélez   +4 more
doaj   +1 more source